Smith & Nephew Plc Directorate Change (7718V)
December 06 2023 - 2:00AM
UK Regulatory
TIDMSN.
RNS Number : 7718V
Smith & Nephew Plc
06 December 2023
Smith+Nephew announces change in Audit Committee Chair
6 December 2023
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology
business , announces that Rick Medlock has notified the Board of
his decision not to submit himself for re-election as a
Non-Executive Director at the next annual general meeting of the
Company.
Jez Maiden, Non-Executive Director, will be appointed Chair of
the Audit Committee with effect from 1 March 2024.
The Board would like to thank Rick for his commitment and
contribution to the Board and the Company and to congratulate Jez
on his new appointment.
Enquiries
Investors / Analysts
Andrew Swift
Smith+Nephew +44 (0) 1923 477433
Media
Charles Reynolds
Smith+Nephew +44 (0) 1923 477314
Susan Gilchrist / Ayesha Bharmal
Brunswick +44 (0) 20 7404 5959
Jez Maiden Biography
Key skills and competencies
Jez joined the Board in 2023 and has extensive financial
experience across a diverse range of industries and sectors. Jez
was Chief Financial Officer of 5 UK-listed companies over a period
of 24 years and has served as a Non-Executive Director on boards of
companies addressing strategic and operational challenges across a
number of different industries, including life-sciences and
healthcare. He was previously Chair of the Audit Committee at
Synthomer PLC and PZ Cussons plc.
Current external appointments
Senior Independent Director, Travis Perkins plc. Non-Executive
Director and member of the Audit Committee at Intertek Group
plc.
Previous experience
Jez retired in 2023 as Group Finance Director at Croda
International plc, the FTSE 100 global speciality chemicals
company, and previously held similar roles at National Express
Group plc and Northern Foods Limited. He has served as the Senior
Independent Director at Synthomer PLC and at both PZ Cussons plc
and Synthomer PLC he chaired the Audit Committee and served on the
Remuneration Committee. He is a fellow of the Chartered Institute
of Management Accountants.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that
exists to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 19,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global business units of
Orthopaedics, Advanced Wound Management and Sports Medicine &
ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X , LinkedIn , Instagram or
Facebook .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABLBDDGSGDGXU
(END) Dow Jones Newswires
December 06, 2023 02:00 ET (07:00 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2024 to May 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From May 2023 to May 2024